Pardes initiates Phase II trial of Covid-19 antiviral drug

Pardes Biosciences has initiated a Phase II clinical trial of its oral, direct-acting, antiviral drug candidate, PBI-0451, to treat symptomatic adult Covid-19 patients in the non-hospital setting.